Literature DB >> 12232871

Management of the solitary pulmonary nodule: directed resection.

Joel D Cooper1.   

Abstract

The primary goals in management of a solitary pulmonary nodule are: 1) early detection and treatment of lung cancer at a curable stage; 2) avoidance of unnecessary surgery for benign lesions; 3) efficient, economic use of resources in distinguishing between benign and malignant lesions. Management depends on the nature of the nodule, the nature of the patient, and the approach of the physician or surgeon who assumes responsibility for further evaluation and treatment of the solitary pulmonary nodule. By combining appropriate diagnostic studies, and close personal attention, unnecessary excision of benign nodules can be kept to a minimum, patient anxiety allayed and excision of cancers undertaken with appropriate staging and without compromise of outcome. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12232871     DOI: 10.1053/stcs.2002.33430

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  3 in total

1.  What do you mean, a spot?: A qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules.

Authors:  Renda Soylemez Wiener; Michael K Gould; Steven Woloshin; Lisa M Schwartz; Jack A Clark
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

2.  Solitary pulmonary nodules: consequences for patient quality of life.

Authors:  Irawati Lemonnier; Cédric Baumann; Damien Jolly; Patrick Arveux; Marie-Christine Woronoff-Lemsi; Michel Velten; Francis Guillemin
Journal:  Qual Life Res       Date:  2010-08-09       Impact factor: 4.147

3.  Management of SPN in France. Pathways for definitive diagnosis of solitary pulmonary nodule: a multicentre study in 18 French districts.

Authors:  Kazem Alzahouri; Michel Velten; Patrick Arveux; Marie-Christine Woronoff-Lemsi; Damien Jolly; Francis Guillemin
Journal:  BMC Cancer       Date:  2008-04-10       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.